On 25th January 2023, the National Institute for Health and Care Excellence (NICE) announced that eptinezumab (Vyepti) has been approved for use within the NHS in England for the treatment of episodic migraine.
Eptinezumab is given by infusion once every 12 weeks. It is one of a number of calcitonin gene-related peptide (CGRP) antibody drugs, which are the first medication specifically designed to prevent migraine.
The drug should be available for patients who experience migraine on four or more days a month and who have already failed to respond to at least three other migraine preventive drugs.
Integrated Care Systems (ICSs) in England now have three months to comply with this recommendation.